Your browser doesn't support javascript.
loading
A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Bonora, E; Bryzinski, B; Hirshberg, B; Cook, W.
Affiliation
  • Bonora E; University and University Hospital of Verona, Verona, Italy. Electronic address: enzo.bonora@univr.it.
  • Bryzinski B; AstraZeneca, Gaithersburg, MD, USA.
  • Hirshberg B; MedImmune, LLC, Gaithersburg, MD, USA.
  • Cook W; AstraZeneca, Gaithersburg, MD, USA.
Nutr Metab Cardiovasc Dis ; 26(5): 374-9, 2016 05.
Article in En | MEDLINE | ID: mdl-27033025

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Adamantane / Cardiovascular Diseases / Dipeptidyl Peptidase 4 / Diabetes Mellitus, Type 2 / Dipeptides / Dipeptidyl-Peptidase IV Inhibitors Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Nutr Metab Cardiovasc Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA / CIENCIAS DA NUTRICAO / METABOLISMO Year: 2016 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Adamantane / Cardiovascular Diseases / Dipeptidyl Peptidase 4 / Diabetes Mellitus, Type 2 / Dipeptides / Dipeptidyl-Peptidase IV Inhibitors Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Nutr Metab Cardiovasc Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA / CIENCIAS DA NUTRICAO / METABOLISMO Year: 2016 Document type: Article Country of publication: